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Pharmacokinetic–pharmacodynamic (PK/PD) integration and modelling were
used to predict dosage schedules of oxytetracycline for two pig pneumonia
pathogens, Actinobacillus pleuropneumoniae and Pasteurella multocida. Minimum
inhibitory concentration (MIC) and mutant prevention concentration (MPC)
were determined in broth and porcine serum. PK/PD integration established
ratios of average concentration over 48 h (Cav0–48 h)/MIC of 5.87 and
0.27 lg/mL (P. multocida) and 0.70 and 0.85 lg/mL (A. pleuropneumoniae)
for broth and serum MICs, respectively. PK/PD modelling of in vitro time–kill
curves established broth and serum breakpoint values for area under curve
(AUC0–24 h)/MIC for three levels of inhibition of growth, bacteriostasis and 3
and 4 log10 reductions in bacterial count. Doses were then predicted for each
pathogen, based on Monte Carlo simulations, for: (i) bacteriostatic and bacte-
ricidal levels of kill; (ii) 50% and 90% target attainment rates (TAR); and (iii)
single dosing and daily dosing at steady-state. For 90% TAR, predicted daily
doses at steady-state for bactericidal actions were 1123 mg/kg (P. multocida)
and 43 mg/kg (A. pleuropneumoniae) based on serum MICs. Lower TARs were
predicted from broth MIC data; corresponding dose estimates were 95 mg/kg
(P. multocida) and 34 mg/kg (A. pleuropneumoniae).
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INTRODUCTION
The tetracycline group of antimicrobial drugs, discovered in
1948, has consistently had the highest veterinary sales volume
of the seven drug classes analysed by UK-VARSS (2014). Resis-
tance to oxytetracycline may be similar to that reported for
tetracycline, but this remains to be confirmed. Nevertheless,
according to the Clinical Laboratory Standards Institute (CLSI,
2013), whilst tetracycline is the class representative, MIC and
breakpoint interpretation for tetracycline also apply to oxyte-
tracycline.
Oxytetracycline is a broad-spectrum drug, classified as a bac-
teriostat, when administered at clinical dosages, but in vitro
studies have demonstrated bactericidal actions (Brentnall et al.,
2012; Dorey et al., 2016; Lees et al., 2016). Several pathogens
implicated in pig pneumonia, including mycoplasma species,
were shown historically to be susceptible to the actions of
oxytetracycline. It has been registered for veterinary use in
most European countries and has been in extensive use in farm
animals for more than 60 years. It is therefore still a drug of
considerable scientific and clinical interest.
For the treatment of porcine pneumonia, oxytetracycline has
the advantage of low cost, clinical efficacy in at least some
cases and availability in a long-acting formulation (Lees & Tou-
tain, 2011). Licensed 20–30% w/v strength parenteral formu-
lations of oxytetracycline have persistent actions, because of
the high strength and high dosage used (20–30 mg/kg), lead-
ing to sustained absorption from the reservoir site of intramus-
cular injection. This gives rise to flip-flop pharmacokinetics
(PK) (Nouws & Vree, 1983; Toutain & Raynaud, 1983; Nouws
et al., 1990). In recent years, there have been major advances
in designing dosage schedules of antimicrobial drugs, based on
integration and modelling of pharmacodynamic (PD) and PK
data. These approaches have provided novel strategies for pre-
dicting drug dosages that optimize efficacy and minimize
opportunities for the emergence of resistance (Nielsen et al.,
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2011; Martinez et al., 2012; Nielsen & Friberg, 2013; Papich,
2014; Rey et al., 2014; Vilalta et al., 2014; Lees et al., 2015b).
The most commonly used (PD parameter to determine
potency of antimicrobial drugs is minimum inhibitory concen-
tration (MIC); this is the lowest concentration (based on two-
fold dilutions) that inhibits visible bacterial growth after 16- to
24-h incubation under standard conditions. CLSI guidelines
recommend that MIC results be established for 16–20 h for
most micro-organisms, except fastidious micro-organisms such
as Actinobacillus pleuropneumoniae that require 20- to 24-h
incubation (CLSI VET01-A4 and VET01-S, CLSI, 2013). Also
of increasing interest is mutant prevention concentration
(MPC); this is the concentration preventing the growth of the
least susceptible cells in high-density bacterial populations
(Blondeau et al., 2004). Integration of in vitro generated
potency indices with in vivo-generated PK data has been used
extensively to generate three PK/PD indices, namely the ratios,
maximum plasma concentration (Cmax)/MIC and area under
plasma concentration–time curve (AUC24 h)/MIC, and time
(T) > MIC, the time for which concentration exceeds MIC.
Integrated PK/PD data are commonly supplemented by
in vitro time–kill studies. These generate information on the
time course of antimicrobial action, enabling classification of
drugs as time-, concentration- or co-dependent in their killing
actions. From time–kill studies, numerical values of PK/PD
breakpoints can be determined by PK/PD modelling (Aliabadi
& Lees, 2002; Toutain & Lees, 2004; Mouton et al., 2011;
Martinez et al., 2012; Nielsen & Friberg, 2013; Papich, 2014;
Sidhu et al., 2014; Lees et al., 2015b). These PD and PK data
may be used additionally, with wild-type MIC distributions of
susceptible pathogens, to conduct Monte Carlo simulations
(MCS) to predict doses providing a range of predetermined
levels of kill. Ideally, predicted doses are then correlated with
clinical and bacteriological cures in animal disease models and
clinical trials (Nielsen et al., 2011; Nielsen & Friberg, 2013;
Papich, 2014; Lees et al., 2015b).
With the aims of (i) extending the useful life of older antimi-
crobial drugs and (ii) reducing the likelihood of resistance
emergence and ensuring prudent use of these drugs, there
have been proposals to re-evaluate dose schedules that were
set, in many instances, many years ago (Aliabadi & Lees,
2001; Mouton et al., 2011, 2012; Nielsen et al., 2011; Marti-
nez et al., 2012; Nielsen & Friberg, 2013; Nyberg et al., 2014;
Papich, 2014; Rey et al., 2014; Toutain et al., 2016). The
European Union Committee on Antimicrobial Testing
(EUCAST) approach to dosage re-evaluation has been described
by Mouton et al. (2011). Moreover, the above-named authors
have recognized that a sound scientific approach to setting
dose schedules of antimicrobial drugs is to link PK parameters
and variables with appropriate indices of potency, applying the
general equation for systemically acting drugs (Fig. 1) (Ali-
abadi & Lees, 2001, 2002; Toutain & Bousquet-Melou, 2004;
Toutain & Lees, 2004).
The internationally accepted EUCAST) and CLSI methods
and standards for MIC determinations are based on the use of
artificial broths. These are nonbiological growth media, such
as Mueller Hinton Broth (MHB), formulated on a pathogen-by-
pathogen basis. Whilst such media are specifically designed to
provide optimal in vitro growth conditions, they differ in com-
position from body fluids. Clinical treatment of disease depends
on drug concentration in the biological fluid of the biophase.
Concentration in the latter is driven by the plasma concentra-
tion of free drug. Therefore, for some drug classes, including
tetracyclines and triamilides, it has been proposed that the use
of serum to determine MIC might be more relevant than reli-
ance on determinations in broths (Nightingale & Murakawa,
2002; Brentnall et al., 2013; Honeyman et al., 2015; Lees
et al., 2016; Toutain et al., 2016). This is justified by the fact
that serum, whilst not identical to biophase fluids, such as pul-
monary epithelial lining fluid, is for a given species much clo-
ser in composition than artificial broths.
For the same reason, namely closer approximation to bacte-
rial growth conditions in vivo, comparative time–kill studies
conducted in our laboratory, based on multiples of MIC, have
been conducted in both broths and serum of the species of
interest to establish matrix differences, if any (Illambas et al.,
2013a,b; Potter et al., 2013; Sidhu et al., 2014; Lees et al.,
2015a,b). In vitro time–kill data allow classification of killing
action as time-, concentration- or co-dependent and, by mod-
elling the data, PK/PD breakpoints have been generated for a
given drug against a given pathogen. In conjunction with PK
data and MIC distributions of wild-type organisms, PK/PD
DO:      Daily dose (mg/kg/day) 
Cl:     Body Clearance (per h) 
Breakpoint index: Index for required effect (AUC24 h/MIC) (h) 
Targeted plasma concentration:  MIC90 (µg/mL) 
F%:     Bioavailability (from 0 to 1) 
Fig. 1. Formula for calculation of daily drug
dose based on pharmacokinetic and
pharmacodynamic variables.
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breakpoints have been used to predict dosages for a range of
target attainment rates (TAR) (Toutain & Lees, 2004; Sidhu
et al., 2010, 2014; Toutain et al., 2016).
The aims of this study were (i) to determine the plasma con-
centration–time profile for oxytetracycline administered to pigs
intramuscularly at the recommended dosage of 20 mg/kg and
derive PK variables by noncompartmental analysis; (ii) to inte-
grate in vivo PK variables with in vitro PD indices of potency
(MIC and MPC) to determine values of Cmax/MIC, Cmax/MPC,
T > MIC, T > MPC and ratios of average concentration
(Cav)/MIC and Cav/MPC for A. pleuropneumoniae and Pasteurella
multocida; (iii) to model data from time–kill studies of A. pleu-
ropneumoniae and P. multocida in order to generate PK/PD
breakpoint values of AUC24 h/MIC for three levels of bacterial
kill, bacteriostasis, bactericidal and 4 log10 reduction in inocu-
lum count; (iv) to use PK and PK/PD breakpoints, with serum
protein binding data and literature MIC distributions in Monte
Carlo simulations to estimate dose schedules required for: (i)
bacteriostatic and bactericidal levels of kill; (ii) for 50% and
90% TAR; and (iii) for single dosing and daily dosing at
steady-state.
MATERIALS AND METHODS
Origin, storage and selection of bacterial isolates
Twenty isolates of P. multocida were supplied by Don Whitley
Scientific (Shipley, West Yorkshire, UK). They also supplied
three ATCC reference strains, A. pleuropneumoniae ATCC
27090, Enterococcus faecalis ATCC 29212 and Escherichia coli
ATCC 25922, to validate MIC determinations. Eight isolates of
A. pleuropneumoniae were supplied by A. Rycroft (Royal Veteri-
nary College, Hawkshead Campus, Hatfield, Herts., UK). All
P. multocida and A. pleuropneumoniae isolates were derived from
EU field cases of pig pneumonia. Based on three criteria, six
isolates of each species were selected: (i) ability to grow loga-
rithmically in both broth and pig serum; (ii) susceptibility to
oxytetracycline in disc diffusion assays (data not shown); and
(iii) the highest and lowest broth MICs and four isolates with
intermediate MICs, determined using twofold dilutions (data
not shown). This initial selection procedure ensured that all
isolates could be used in subsequent investigations in both
growth media and that they comprised a small but diverse
range of susceptible isolates.
Determination of minimum inhibitory and mutant prevention
concentrations
Minimum inhibitory concentrations were determined by
microdilution for six isolates each of A. pleuropneumoniae and
P. multocida, except where stated in accordance with CLSI
guidelines (2013), using artificial broths, cation-adjusted Muel-
ler Hinton Broth (CAMHB) for P. multocida and Columbia
Broth (CB) supplemented with nicotinamide adenine dinu-
cleotide (NAD) for A. pleuropneumoniae. CSLI recommended
artificial medium for A. pleuropneumoniae culture is veterinary
fastidious medium; this was replaced for CB as improved bacte-
rial growth was determined and the lack of blood clot forma-
tion made MIC endpoints easier to establish. To improve
accuracy of estimates for each isolate, five sets of overlapping
twofold serial dilutions of oxytetracycline were prepared in 96-
well plates and each determination was made in triplicate,
instead of the CLSI standard which uses single twofold dilu-
tions. This was considered necessary, because of the small
number of isolates of each species used in this study. In addi-
tion, the guidelines were adapted using pig serum in place of
broth to enable comparison of potency in the two matrices,
again with five overlapping sets of twofold dilutions and deter-
minations in triplicate. Methods were as described by Dorey
et al. (2016).
Mutant prevention concentrations were determined by
applying a high count bacterial suspension (1–2 9 1011 col-
ony-forming units (CFU)/mL) onto an agar plate containing
drug concentrations 1, 2, 4, 8, 16, 32, 64 and 128 multiples
of the MIC for each isolate. The concentration ranges were
narrowed down two further times. Plates were incubated at
37 °C for 72 h and checked for growth every 24 h. MPC was
the lowest oxytetracycline concentration inhibiting bacterial
growth completely after 72-h incubation. The method was val-
idated against that developed by Blondeau et al. (2004) and
described by Dorey et al. (2016). Each experiment was repeated
in triplicate for six isolates of each test organism in broth and
serum matrices.
Oxytetracycline pharmacokinetics
Individual animal plasma concentration–time profiles for oxyte-
tracycline were supplied by Norbrook Laboratories Ltd. for two
oxytetracycline containing products (Alamycin LA, Norbrook
Laboratories, Northern Ireland and Terramycin LA, Pfizer, UK).
The study was approved by the company’s Ethics Committee
and was Good Laboratory Practice compliant. All pigs were
Landrace Cross males, aged 2 months. Each product was
administered intramuscularly at a dosage of 20 mg/kg. As the
two products had been shown to be bioequivalent, the data
were pooled, to provide a data set of 14 animals (n = 6 for Ter-
ramycin LA and n = 8 for Alamycin LA) for noncompartmen-
tal analysis (NCA) using WinNonLin V6.5 (Pharsight
Corporation, Mountain View, CA, USA). Variables calculated
were Cmax, Cav, AUC, area under first moment curve (AUMC),
time of maximum concentration (Tmax), clearance scaled by
bioavailability (Cl/F), terminal half-life (T1/2) and mean resi-
dence time from the time of dosing to the time of last measure-
able concentration (MRTlast). Three time periods were
investigated (0–48 h, 0–24 h and 24–48 h) for determination
of average concentrations.
PK/PD integration
Pharmacokinetic–pharmacodynamic indices, calculated using
individual animal PK values and mean MIC and MPC values,
were as follows: (i) Cmax/MIC, T > MIC and Cav/MIC ratios for
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three time periods, 0–24 h, 24–48 h and 0–48 h; (ii) Cmax/
MPC, T > MPC and Cav/MPC ratios for three time periods,
0–24 h, 24–48 h and 0–48 h. T > MIC and T > MPC were
calculated using the equation C = A*exp(b*t), where C is the
predicted drug concentration at time t, A is the concentration
at Tlast, b is lambda_z, slope of the terminal phase, calculated
by NCA with at least three concentration–time points in the
terminal phase. Compared with the prediction using compart-
mental modelling, the above method generated better fitting,
with significantly smaller residuals.
PK/PD breakpoint determination
For each pathogen, in vitro growth inhibition curves for oxyte-
tracycline were determined using eight multiples of MIC, as
previously described (Dorey et al., 2016). Each test was
repeated in triplicate for six isolates each of A. pleuropneumoniae
and P. multocida in both broth (CB and CAMHB, respectively)
and pig serum. The lower limit of quantification (LLOQ) was
33 CFU/mL. The sigmoidal Emax equation (Fig. 2) was then
used to model AUC24 h/MIC data. Using the calculated param-
eters with this equation, log10 change in CFU/mL against
AUC24 h/MIC was simulated (Fig. 3). AUC24 h/MIC PK/PD
breakpoints were determined for three levels of growth inhibi-
tion: E = 0, bacteriostatic, that is 0 log10 reduction in CFU/mL
after 24-h incubation; E = 3, bactericidal, 3 log10 reduction
in CFU/mL; and E = 4, 4 log10 reduction in bacterial count.
Dose determination
For dose prediction using the deterministic approach, average
values of PK and PK/PD breakpoint values were used, together
with MIC90 values for P. multocida and A. pleuropneumoniae for
tetracycline obtained from the literature (de Jong et al., 2014).
+
E Effect 
E0 Bacterial growth after 24-h incubation in the absence of drug (control samples), 
 expressed as log10 CFU/mL subtracted from the initial inoculum expressed as 
 log10 CFU/mL after 24-h culture 
Emax The maximal obtainable effect in log10 CFU/mL over 24 h 
EC50     AUC24 h /MIC producing 50% of maximum response (h) 
Ce AUC24 h /MIC (h) 
N The Hill coefficient which describes the gradient of the AUC24 h /MIC-
 effect  curve 
Fig. 2. The sigmoidal Emax equation used to
model time–kill data by nonlinear regression
(Lees et al., 2015a).
Fig. 3. Typical example plot of AUC24 h/MIC
vs. change in bacterial count (log10 CFU/mL)
obtained from in vitro time–kill data for
oxytetracycline. Each point represents an
experimental value showing time–kill 24-h
data point of one isolate, one repeat and one
matrix. The curve is the line of best fit based
on the sigmoidal Emax equation. Colour figure
can be viewed at wileyonlinelibrary.com.
© 2017 The Authors. Journal of Veterinary Pharmacology and Therapeutics Published by John Wiley & Sons Ltd.
4 L. Dorey et al.
MIC distribution data for oxytetracycline were not available
from a European source (vide infra). However, MIC and break-
point interpretation for tetracycline also apply to oxytetracy-
cline, according to CLSI (CLSI, 2013).
For dose determination using Monte Carlo simulations, data
input comprised: (i) whole body clearance scaled by bioavail-
ability; (ii) free drug concentration in plasma; (iii) AUC24 h/MIC
breakpoints derived from time–kill curves by PK/PD modelling;
and (iv) MIC field distribution data for tetracycline as indicated
above (Fig. 4). In addition, for comparative purposes, more lim-
ited Japanese oxytetracycline MIC distribution data for P. mul-
tocida in pigs were used (Yoshimura et al., 2001). Monte Carlo
simulations were based on numerical values and incidence of
each input variable and predicted: the daily dose at steady-
state (Fig 5); single loading doses for three time periods, 0–24,
0–48 and 0–72 h; and doses for three levels of bacterial kill,
as described by Lees et al. (2015a). All dosages were computed
using Monte Carlo simulations in Oracle Crystal Ball (Oracle
Corporation, Redwood Shores, CA, USA) for TAR of 50% and
90%. For the literature MIC distributions, values were cor-
rected using the serum:broth MIC ratio, as the reported MIC
literature values were determined in broth. The probabilities of
distribution for the dosage estimation were run for 50 000
simulated trials.
RESULTS
Minimum inhibitory and mutant prevention concentrations
Minimum inhibitory concentrations and MPCs were deter-
mined for six isolates each of P. multocida and A. pleuropneumo-
niae, and each was determined in broth and pig serum.
Geometric mean MIC values in lg/mL (SD) for P. multocida
were 0.30 (0.12) and 6.48 (1.45), respectively. Corresponding
values for A. pleuropneumoniae were 2.50 (0.70) and 2.08
(0.43) (Dorey et al., 2016). Mean MPC values in lg/mL (SD)
for P. multocida were 6.84 (2.76) and 142.8 (33.3) determined
in broth and serum, respectively. For A. pleuropneumoniae, MPC
values were 44.4 (12.63) and 35.1 (6.66) lg/mL, respectively
(Dorey et al., 2016). For each pathogen, MPC:MIC ratios were
similar in serum and broth.
Oxytetracycline pharmacokinetics
From plasma concentration–time data, PK variables were cal-
culated for 14 pigs, comprising data for six animals receiving
product A (Terramycin LA) and eight pigs administered pro-
duct B (Alamycin LA). Each product was administered intra-
muscularly at a dosage of 20 mg/kg, and the two products
Fig. 4. Tetracycline MIC frequency distributions for P. multocida (n = 105) and A. pleuropneumoniae (n = 110). Data obtained using CLSI methods
(de Jong et al., 2014). Sampling period covered 2002–2006 from European countries. Oxytetracycline MIC frequency distribution for P. multocida
(n = 61). MIC data obtained using agar dilution method. Sampling period covered 1994–1998 from Japan. Colour figure can be viewed at wileyon
linelibrary.com.
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were bioequivalent. Table 1 indicates mean values for each
variable, determined by noncompartmental analysis.
PK/PD integration
Pharmacokinetic–pharmacodynamic integration established the
parameters Cmax/MIC, T > MIC and concentration averages
(Cav)/MIC, over three time periods (0–48, 0–24 and 24–48 h)
(Table 2). Integrated values were numerically much greater for
broth MIC than for serum MIC for P. multocida; Cav0–24/MIC
was 9.01 in broth and 0.42 in serum, but for A. pleuropneumo-
niae data were similar between the two media, Cav0–24/MIC
being 1.08 and 1.30, respectively. For P. multocida, the plasma
concentration remained above the broth MIC for 52.5 h, and
T > MIC for serum was 3.62 h. Corresponding values for
A. pleuropneumoniae were 11.0 and 15.5 h.
Integration of PK and PD data for MPC is presented in
Table 3. All ratios were much lower than the PK:MIC ratios,
as a consequence of the MPC:MIC ratios, which were 22.8:1
(serum) and 22.0:1 (broth) for P. multocida and 16.9:1 (serum)
and 17.9:1 (broth) for A. pleuropneumoniae. Cmax/MPC ratios
were less than 1 for both pathogens and both matrices.
Table 1. Pharmacokinetic variables (mean, standard deviation,
n = 14) for oxytetracycline
Variable Units Mean SD
Cmax mg/L 5.67 2.40
AUC hmg/L 84.5 14.7
AUMC hhmg/L 1244 221
Tmax h 0.92 1.05
Cl/F L/h/kg 0.22 0.04
T1/2 h 12.9 1.83
MRTlast h 14.7 1.27
Pharmacokinetic variables were determined by noncompartmental
analysis for oxytetracycline administered intramuscularly at a dosage
of 20 mg/kg. Values are geometric means except for Tmax (arithmetic
mean) and T1/2 (harmonic mean). Cmax, maximum concentration;
AUC, area under plasma concentration–time curve; AUMC, area under
first moment curve; Tmax, time taken to reach maximum concentration;
Cl/F, drug clearance scaled by bioavailability; T1/2, terminal half-life;
MRTlast, mean residence time from the time of dosing to the time of last
measureable concentration.
Table 2. Integration of pharmacokinetic and pharmacodynamic vari-
ables for oxytetracycline for broth and serum MICs (mean and stan-
dard deviation)
Organism Parameter Units
Broth Serum
Mean SD Mean SD
Pasteurella
multocida
Cav0–48/MIC 5.87 1.02 0.27 0.05
Cav0–24/MIC 9.01 1.75 0.42 0.08
Cav24–48/MIC 3.28 0.81 0.15 0.04
Cmax/MIC 18.9 7.99 0.88 0.37
T > MIC h 52.5 5.70 3.62 7.13
Actinobacillus
pleuropne-
umoniae
Cav0–48/MIC 0.70 0.12 0.85 0.15
Cav0–24/MIC 1.08 0.21 1.30 0.25
Cav24–48/MIC 0.39 0.10 0.47 0.12
Cmax/MIC 2.27 0.96 2.73 1.15
T > MIC h 11.0 3.71 15.5 3.38
Individual animal pharmacokinetic data for 14 animals divided by
mean MICs for six isolates of each species measured in broth and
serum. Cav = average concentration calculated for time periods 0–48,
0–24 and 24–48 h. Cmax = maximum plasma concentration (lg/mL);
T > MIC = time for which plasma concentration exceeds MIC (h).
(a)
(b)
(c)
Fig. 5. Formulae for calculation of the loading dose for 48-h duration of action, where equation A can be expressed as equation B and simplified as
equation C. K10 = elimination rate constant; s = dosing interval in h; Cl48 = body clearance over 48 h; KPD breakpoint = AUC divided by 24;
MICDistribution = MICs determined from epidemiological surveys; F = bioavailability (from 0 to 1); fu = fraction of drug not bound to protein binding.
Table 3. Integration of pharmacokinetic and pharmacodynamic vari-
ables for oxytetracycline for broth and serum MPCs (mean and stan-
dard deviation)
Organism Parameter Units
Broth Serum
Mean SD Mean SD
Pasteurella
multocida
Cav0–48/MPC 0.26 0.04 0.01 0.00
Cav0–24/MPC 0.40 0.08 0.02 0.00
Cav24–48/MPC 0.14 0.04 0.01 0.00
Cmax/MPC 0.83 0.35 0.04 0.02
T > MPC h 0 0
Actinobacillus
pleuropneumoniae
Cav0–48/MPC 0.04 0.01 0.05 0.01
Cav0–24/MPC 0.06 0.01 0.08 0.01
Cav24–48/MPC 0.02 0.01 0.03 0.01
Cmax/MPC 0.13 0.05 0.16 0.07
T > MPC h 0 0
Individual animal pharmacokinetic data for 14 animals divided by
mean MPCs for six isolates of each species measured in broth and
serum. Cav = average concentration calculated for time periods 0–48,
0–24 and 24–48 h. Cmax = maximum plasma concentration (lg/mL);
T > MPC = time for which plasma concentration exceeds MPC (h).
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PK/PD modelling
Eight oxytetracycline concentration multiples of MIC, ranging
from 0.25 to 8 9 MIC, were used in time–kill studies for six
isolates each of A. pleuropneumoniae and P. multocida for 24-h
incubation periods. This range established bacteriostatic, bacte-
ricidal and 4 log10 reductions in count at 24 h. Breakpoint
values of AUC24 h/MIC producing these levels of growth inhibi-
tion are presented in Tables 4 (P. multocida) and 5 (A. pleurop-
neumoniae).
Dividing the AUC24 h/MIC ratios by 24 yields the concentra-
tions, as MIC multiples, producing bacteriostatic, bactericidal and
4 log10 reductions in count. These are breakpoint KPD values;
they are more readily comprehended than the term AUC24 h/MIC.
KPDs were 1.10, 2.89 and 4.30, respectively, for P. multocida
in broth and 1.01, 2.18 and 3.02 for this pathogen in serum.
Corresponding values for A. pleuropneumoniae were 1.10, 1.64
and 1.89 (broth) and 1.38, 2.31 and 3.32 (serum).
Average dose determination at steady-state
Based on mean Cl/F and published values for MIC90 for tetra-
cycline (de Jong et al., 2014), the calculated daily doses for
bactericidal level of activity were 1748 mg/kg for P. multocida
and 535 mg/kg for A. pleuropneumoniae (Table 6). However,
when the worst-case scenario was predicted, using the animal
with highest clearance (Cl/F = 0.30 L/h/kg) and hence the
most rapid clearance, the predicted dose for a bactericidal level
of kill was 2381 mg/kg for P. multocida and 1269 mg/kg for
A. pleuropneumoniae.
Dose determination by Monte Carlo simulation
Monte Carlo simulations were conducted using the distribution
of Cl/F, the distribution of wild-type MICs for tetracycline (de
Jong et al., 2014), serum free drug concentration, previously
shown to be 29% of total concentration in the pig (Dorey et al.,
2016), and PK/PD AUC24 h/MIC breakpoint values generated
in this study.
Predicted once-daily doses at steady-state PKs are presented
in Table 7. For A. pleuropneumoniae for 50% TAR and a bacte-
riostatic action, doses were similar, when calculated using
broth and serum MICs, 18 and 17 mg/kg, respectively. For a
bactericidal level of kill and 90% TAR, corresponding doses
were 34 and 43 mg/kg. In marked contrast, for P. multocida,
there were large differences in predicted doses, depending on
whether broth or serum MICs were used. For example, for
50% TAR and a bacteriostatic action, doses were 12 mg/kg
(broth) and 232 mg/kg (serum) whilst for 90% TAR and a
bactericidal level of kill, corresponding doses were 95 and
1123 mg/kg.
Pasteurella multocida MIC distributions for a smaller number
of oxytetracycline isolates of Japanese origin (Yoshimura et al.,
2001) differed from the tetracycline MIC distributions of Euro-
pean origin obtained by de Jong et al. (2014); for example, the
MIC90s were 12.5 and 2 lg/mL, respectively. Figure 4 demon-
strates the MIC distribution data after applying epidemiological
cut-off values (ECOFF) to ensure normally distributed data.
Table 4. Pharmacokinetic–pharmacodynamic modelling for Pasteurella
multocida from time–kill data (mean and standard deviation, n = 6)
Parameter (units)
Broth Serum
Mean SD Mean SD
Log E0 (CFU/mL) 2.72 0.30 2.28 0.50
Log Emax (CFU/mL) 4.52 1.35 5.71 1.62
Log Emax  Log E0 (CFU/mL) 7.24 1.05 7.98 1.11
Gamma 4.24 3.05 2.63 1.40
AUC24 h/MIC for
bacteriostatic action (h)
26.4 7.88 24.3 6.66
AUC24 h/MIC50 (h) 33.4 3.84 39.9 17.3
AUC24 h/MIC for
bactericidal action (h)
69.3 42.8 52.3 16.4
AUC24 h/MIC for
4 log10 reduction (h)
103.3 54.8 72.4 26.3
E0 = difference in number of organisms (CFU/mL) in control sample in
absence of drug between time 0 and 24 h; Emax = difference in number
of organisms (CFU/mL) in the presence of oxytetracycline between time
0 and 24 h; AUC24/MIC50 = concentration reducing count to 50% of
the Emax; Gamma = slope of the curve; detection limit = 33 CFU/mL.
Table 5. Pharmacokinetic–pharmacodynamic modelling for Actinobacil-
lus pleuropneumoniae from time–kill data (mean and standard deviation,
n = 6)
Parameter (units)
Broth Serum
Mean SD Mean SD
Log E0 (CFU/mL) 2.02 0.37 2.46 0.85
Log Emax (CFU/mL) 6.48 0.37 5.09 2.38
Log Emax  Log E0 (CFU/mL) 8.50 0.00 7.45 1.53
Gamma 3.89 0.63 3.66 3.02
AUC24 h/MIC for
bacteriostatic action (h)
26.3 2.07 33.1 16.7
AUC24 h/MIC50(h) 35.6 2.74 40.1 20.4
AUC24 h/MIC for bactericidal
action (h)
39.5 3.07 55.4 19.2
AUC24 h/MIC for 4 log10
reduction (h)
45.4 4.24 79.7 23.6
E0 = difference in number of organisms (CFU/mL) in control sample in
absence of drug between time 0 and 24 h; Emax = difference in number
of organisms (CFU/mL) in the presence of oxytetracycline between time
0 and 24 h; AUC24/MIC50 = concentration reducing count to 50% of
the Emax; Gamma = slope of the curve; detection limit = 33 CFU/mL.
Table 6. Predicted daily doses calculated by deterministic approach
Daily doses (mg/kg)
Pasteurella
multocida
Actinobacillus
pleuropneumoniae
Bacteriostatic 813 268
Bactericidal 1748 535
4 log10 count reduction 2421 777
MIC90 for P. multocida was 2 lg/mL and 16 lg/mL for A. pleuropneu-
moniae based on tetracycline distribution data (de Jong et al., 2014).
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Therefore, predicted TAR dosages were even higher for the
Japanese MIC oxytetracycline distributions. Thus, for 50% TAR
and bacteriostasis doses were 30 mg/kg (broth MIC) and
595 mg/kg (serum MIC), whilst for 90% TAR and a bactericidal
level of kill, corresponding doses were 189 and 2237 mg/kg
(Table 8).
The single oxytetracycline doses predicted to achieve three
levels of kill (0, 3 and 4 log10 decreases in count) for three
durations of action (24, 48 and 72 h) are presented in
Table 9. For a duration of action of 24 h and a bacteriostatic
level of kill, the 50% TAR single dosages, using serum/broth
oxytetracycline MICs and tetracycline wild-type distribution
data, were 333/17 mg/kg (P. multocida) and 21/25 mg/kg
(A. pleuropneumoniae). Bactericidal levels of kill for a duration
of action of 48 h at 90% TAR, also using tetracycline MIC dis-
tributions and serum/broth MIC data, were 3462/209 mg/kg
for P. multocida and 84/76 mg/kg for A. pleuropneumoniae.
Doses were higher for P. multocida when predicted using oxyte-
tracycline distribution data (Table 10).
DISCUSSION
The objective of this study was to predict doses for oxytetracy-
cline for the pig pneumonia pathogens, P. multocida and
A. pleuropneumoniae based on principles of PK/PD integration
and modelling and the application of Monte Carlo simulation.
Pharmacokinetics
Plasma concentration–time data for oxytetracycline were deter-
mined for a small number (14) of healthy pigs of the same age
and breed and for two products. In extending the present find-
ings, it will, in future studies, be appropriate to obtain data
from greater animal numbers of both sexes and differing ages
and breeds and in diseased as well as healthy pigs. Thus, popu-
lation PK data, derived from field studies, can be used to deter-
mine the impact of disease on clearance and bioavailability, Cl/
F being a major determinant of dosage predictions (Toutain
et al., 2016). Nevertheless, the more limited and less variable
data used in this study illustrate the principles of integrating
PK with PD data to predict TAR dosages.
Pharmacodynamics
In this study, a small number of isolates, six for each of two
pathogens, were used in PK/PD integration and modelling
approaches to dose determination; the question arises whether
they are representative of the much larger number of wild-type
isolates of these organisms. Clearly, whilst sample size was
small, it nevertheless may be noted that: (i) the unavoidable
inaccuracy of each individual MIC potency estimate was
reduced from potentially approaching 100% (as when single
two-dilutions are used using CLSI standards) to not greater
than 20% by the use of five overlapping sets of twofold dilu-
tions; (ii) mean broth MICs for oxytetracycline in this study
was 2.5 lg/mL (A. pleuropneumoniae), and this may be
compared with broth MIC50 and MIC90 values of 1.0 and
16.0 lg/mL (A. pleuropneumoniae) reported for tetracycline by
de Jong et al. (2014). Corresponding values for P. multocida
were 0.30 lg/mL (this study) and 0.50 and 2.0 lg/mL for
tetracycline (de Jong et al., 2014); and (iii) the present data
were supported by a second potency index, namely MPC, and
the proportional increase in potency (MPC:MIC ratio) was simi-
lar for determinations in both broth and serum for both
organisms.
PK/PD integration
Pharmacokinetic–pharmacodynamic integration provided an
initial and tentative approach for evaluating efficacy of cur-
rently recommended oxytetracycline dose schedules for the
pathogens, P. multocida and A. pleuropneumoniae. Thus,
plasma oxytetracycline T > MIC values over the period
0–48 h were 11.0 and 15.5 h in broth and serum, respec-
tively, for A. pleuropneumoniae. Corresponding T > MICs for
P. multocida were 52.5 h (broth MIC) and 3.6 h (serum
MIC). Therefore, prediction of efficacy from PK/PD integra-
tion was broadly similar for potency measured in serum and
broth for the former species, but markedly different for the
latter pathogen. If it is accepted that potency measured in
Table 7. Predicted daily doses at steady-state based on tetracycline
MIC distribution data (de Jong et al., 2014) and using broth and serum
pharmacodynamic data
Daily doses
(mg/kg)
Target attainment rate
50% 90%
Broth Serum Broth Serum
Pasteurella
multocida
Bacteriostatic 12 232 36 730
Bactericidal 30 357 95 1123
4 log10 reduction 45 421 142 1323
Actinobacillus
pleuropneumoniae
Bacteriostatic 18 17 23 22
Bactericidal 26 33 34 43
4 log10 reduction 30 44 40 58
Monte Carlo simulations predicting 50% and 90% target attainment
rate dosages at steady-state for three levels of bacterial kill.
Table 8. Predicted daily doses at steady-state based on oxytetracycline
MIC distribution data (Yoshimura et al., 2001) and using broth and
serum pharmacodynamic data for Pasteurella multocida
Predicted daily
doses (mg/kg)
Target attainment
rate
50% 90%
Broth Bacteriostatic 30 72
Bactericidal 78 189
4 log10 reduction 116 282
Serum Bacteriostatic 595 1453
Bactericidal 916 2237
4 log10 reduction 1079 2635
Monte Carlo simulations predicting 50% and 90% target attainment
rate dosages at steady-state for three levels of bacterial kill.
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serum is more likely to reflect activity in the biophase (pul-
monary epithelial lining fluid for these pathogens) then some
efficacy in clinical subjects against A. pleuropneumoniae (espe-
cially if pathogen load in the biophase is low to moderate)
might be expected. For P. multocida, on the other hand, the
expectation would be of very limited or no efficacy, insofar
as it depends solely on a direct killing action of oxytetracy-
cline. However, in the absence of high-quality clinical trial
data, the integrated PK/PD index (and its numerical value)
that best correlates with bacteriological cure is not known
and can only be surmised.
As MPCs were 17- to 23-fold greater than corresponding
MICs and as MPC:MIC ratios were, moreover, independent of
growth matrix, the integration of PK with PD data indicated
that plasma concentrations of oxytetracycline could not be
achieved, with clinical dosages of oxytetracycline in healthy
pigs, which would ensure the eradication of the least sensitive
subpopulation in a given colony for both bacterial species.
PK/PD modelling and breakpoint determination
Pharmacokinetic–pharmacodynamic modelling is an advance
on PK/PD integration, in that it provides breakpoint values
for a given drug against a particular pathogen obtained from
a given animal species. In addition, it describes the whole
sweep of the concentration–effect relationship, so that any
predetermined level of in vitro activity, ranging from bacte-
riostasis to virtual eradication (indicated by the breakpoint
AUC24 h/MIC index) can be determined. In this study, break-
point values for each level of growth inhibition, 0 log10,
3 log10 and 4 log10 reductions in count, were similar
between the two growth matrices; this is not unexpected as,
although MICs in broth and serum differed for P. multocida,
the breakpoint values are based on MIC multiples. However,
there were trends for increased interisolate variability with
increasing level of kill, especially for P. multocida (Tables 4
and 5). This variability might translate to clinical efficacy
variability for this pathogen, although the dose determina-
tion data imply little or no efficacy from a direct killing
action of oxytetracycline (vide infra).
Table 9. Single doses for 24-, 48- and 72-h durations of action based on tetracycline MIC distribution data (de Jong et al., 2014) and using broth
and serum pharmacodynamic data
Dose duration Level of bacterial kill
Target attainment rate
Broth Serum
50% 90% 50% 90%
Pasteurella multocida 0–24 h Bacteriostatic 17 50 333 1012
Bactericidal 43 131 716 2175
4 log10 reduction 65 196 992 3014
0–48 h Bacteriostatic 25 80 512 1611
Bactericidal 67 209 1102 3462
4 log10 reduction 99 312 1526 4796
0–72 h Bacteriostatic 36 112 719 2270
Bactericidal 93 295 1545 4879
4 log10 reduction 139 439 2141 6759
Actinobacillus pleuropneumoniae 0–24 h Bacteriostatic 25 33 21 28
Bactericidal 37 49 41 55
4 log10 reduction 43 57 60 80
0–48 h Bacteriostatic 39 51 33 42
Bactericidal 58 76 64 84
4 log10 reduction 67 87 93 122
0–72 h Bacteriostatic 54 71 45 59
Bactericidal 81 106 90 118
4 log10 reduction 94 122 131 171
Monte Carlo simulations predicting 50% and 90% target attainment rates for three levels of bacterial kill and three action durations.
Table 10. Single doses for 24-, 48- and 72-h durations of action based
on oxytetracycline MIC distribution data (Yoshimura et al., 2001) and
using broth and serum pharmacodynamic data
Dose duration Level of bacterial kill
Target attainment rate
Broth Serum
50% 90% 50% 90%
0–24 h Bacteriostatic 42 103 841 2088
Bactericidal 109 28 1807 4487
4 log10 reduction 163 404 2504 6215
0–48 h Bacteriostatic 65 159 1305 3211
Bactericidal 169 417 2804 6899
4 log10 reduction 417 621 3885 9557
0–72 h Bacteriostatic 91 223 1838 4503
Bactericidal 238 584 3949 9676
4 log10 reduction 355 871 5471 13 403
Monte Carlo simulations predicting 50% and 90% target attainment
rates for three levels of bacterial kill and three action durations.
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Dosage prediction
The deterministic approach to dosage prediction provides a
useful estimate of once-daily doses at steady-state, based on
MIC90 as a single value and the average values for other
variables. It does not take into account, however, either of
variability or incidence of each input variable, such as clear-
ance or AUC/MIC, as dose is calculated using mean values.
Nevertheless, it comprises an initial evaluation prior to use of
Monte Carlo simulations to estimate population doses for each
selected TAR, which is a dose encompassing a given per-
centile of the target population, for example, 50% or 90%
and for three levels of bacterial kill. Moreover, TAR once-daily
doses have been determined for maintaining efficacy under
steady-state conditions, as well as for TAR single doses over
24, 48 or 72 h time periods, that is either for a single or a
loading dose, in the latter case possibly to be repeated after a
selected time interval.
The Monte Carlo simulation with PK/PD modelling basis for
predicting dosage, for subsequent evaluation in clinical trials,
has the advantage of taking into account all important PK and
PD variables impinging on bacteriological kill. Furthermore,
basing potency estimates on serum as a growth matrix may
have greater relevance to in vivo conditions than MIC deter-
mined in broths, whilst recognizing that serum, although simi-
lar, is not identical in composition to the biophase at infection
sites. Moreover, Monte Carlo simulations predict doses, allow-
ing for incidence within MIC distributions and encompassing
best, worst and all intermediate case scenarios for distributions
of Cl/F and breakpoint AUC24 h/MIC ratios.
These clear advantages have led to the widespread applica-
tion of Monte Carlo simulations to predict dosages (Nielsen
et al., 2011; Martinez et al., 2012; Mouton et al., 2012;
Brentnall et al., 2013; Nielsen & Friberg, 2013; Papich,
2014; Rey et al., 2014; Sidhu et al., 2014; Lees et al.,
2015a; Toutain et al., 2016). Nevertheless, there are inevita-
ble limitations to study methodology. For example, for this
study MIC distribution data were extracted from the litera-
ture, and the number of isolates was limited (230 for
P. multocida and 220 for A. pleuropneumoniae). Moreover, they
were obtained from one geographical location (Europe) for
tetracycline, a drug with likely similar but not necessarily
identical antimicrobial profile to oxytetracycline. For CLSI
(2013), tetracycline is the class representative but it is pro-
posed that MIC tetracycline distribution also applies to oxyte-
tracycline. Comparing tetracycline MIC distribution for
European isolates against Japanese oxytetracycline MIC distribu-
tion for P. multocida indicated MIC ranges of 0.2–12.5 lg/mL
for oxytetracycline (including likely resistant isolates) and
0.25–32 lg/mL for tetracycline (including likely resistant iso-
lates). MIC50 and MIC90 differed, 1.56 and 12.5 lg/mL,
respectively, for oxytetracycline, and corresponding values for
tetracycline were 0.5 and 2.0 lg/mL
Whilst the interisolate variability in PK/PD breakpoint values
was small to moderate in the present study, estimates were
based on only six isolates for each species. The time–kill studies
used fixed drug concentrations (eight multiples of MIC) for a
fixed time period. In clinical use, on the other hand, plasma
drug concentrations would first increase and then decrease
after intramuscular dosing, exposing organisms to a continu-
ously variable concentration. In future studies, these concerns
could be addressed by increasing numbers of isolates in field
distribution studies and in PK/PD breakpoint estimation stud-
ies. Moreover, exposure of organisms to varying drug concen-
trations could be addressed by use of in vitro pump (e.g. hollow
fibre) methods to simulate in vivo patterns of change in concen-
tration with time (Cadwell, 2012).
Finally, the methodology in this study also does not incorpo-
rate the contribution to pathogen elimination by the body’s
natural defence mechanisms in immune-competent clinical
subjects, nor does it allow for additional potentially beneficial
properties of antimicrobial drugs, such as immunomodulatory
and anti-inflammatory actions (vide infra).
The depot formulations of oxytetracycline licensed to treat
porcine respiratory diseases recommend a single dose of
20 mg/kg to achieve up to four days action duration. Based
on serum MICs, the predicted 90% TAR dosage against
P. multocida was 1123 mg/kg daily (bactericidal action at
steady-state) and 3462 mg/kg (bactericidal action as single
dose and 48-h duration). In similar studies for P. multocida
of calf origin, corresponding doses were 921 and 1523 mg/
kg (Lees et al., 2016). These differences for the two animal
species and the same bacterial species are explained by: simi-
lar values for the AUC24 h/MIC bactericidal breakpoints;
approximately twofold higher values of Cl/F in the pig; differ-
ing free drug fractions in serum (29% in the pig, 48% in
the calf); and differing MIC distribution patterns. For both
animal species, however, it is clear that practicable doses to
achieve a direct killing action of oxytetracycline are likely
not to be attainable.
For A. pleuropneumoniae, predicted dosages for 90% TAR and
bactericidal level of kill were 42.5 mg/kg (daily dose at steady-
state) and 84.3 mg/kg (single dose with 48-h duration). Whilst
still exceeding the recommended dose regimen, these lower
doses for this pathogen compared to P. multocida reflect the
broth:serum potency differences for the two bacterial species.
Serum:broth MIC ratios, after correcting for protein binding in
serum, for six isolates of each species were 6.30:1 (P. multocida)
and 0.24:1 (A. pleuropneumoniae) (Dorey et al., 2016).
In conclusion, it might be noted that tetracyclines have
activities other than direct killing actions, and clinically, these
might contribute to or even account for efficacy.
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